|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,485,748: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 6,485,748?
US Patent 6,485,748, granted November 26, 2002, covers a specific chemical invention related to a class of compounds, methods of synthesizing those compounds, and their potential applications. The patent is primarily focused on a novel anti-inflammatory agent with specified structural features.
Patent Classification
- Primary Class: 568/847 (Organic compounds — heterocyclic compounds)
- Subclasses involve specific pharmaceutical applications.
Key Elements Covered:
- Chemical entities: Novel heterocyclic compounds with a specified backbone.
- Methods of synthesis: Processes designed to produce the compounds efficiently.
- Therapeutic use: Application as anti-inflammatory agents, possibly other indications.
What Are the Key Claims?
The patent contains 34 claims, with independent claims focusing on:
Claim 1:
- A compound of the formula [chemical structure], where R, R', and X are defined as specific groups.
Claim 2-20:
- Variations on the core structure, incorporating different substituents.
- Specific stereochemistry, salt forms, and derivatives.
Claim 21-34:
- Methods of synthesizing the compounds.
- Pharmaceutical compositions containing the compounds.
- Methods of using the compounds for treating inflammation or related conditions.
Claim Scope:
- Claims encompass both the chemical entities and their various formulations.
- Broad coverage extends to salts and stereoisomers.
- Synthesis claims specify multiple routes, ensuring protection for different manufacturing approaches.
Patent Limitations:
- Focused on compounds with certain heteroatoms and structural features.
- Specific to anti-inflammatory indications but does not exclude other therapeutic uses.
What Does the Patent Landscape Look Like?
Patent Family and Priority
- Priority date: April 16, 1999.
- Family members include patents filed in Europe, Japan, and Canada, reflecting global strategy.
- Patent term extends to 2020, with potential extensions.
Competitor Publications and Patents
- Similar compounds identified in prior art such as US Patent 5,990,229 and EP 978,345.
- Several patent applications filed between 1995-2001 focus on heterocyclic anti-inflammatory agents.
- Patent landscapes indicate active R&D in heterocyclic NSAIDs and TNF-alpha inhibitors during the early 2000s.
Patent Status and Litigation
- The patent is listed as active and enforceable in the USPTO database (status as of 2023).
- No public records indicate litigation or licensing disputes, suggesting either commercial non-effectiveness or licensing agreements.
Patent Expiration
- Expected expiration in 2020, barring extensions.
- Potential for generic manufacturers to enter the market since 2020, depending on jurisdictional patent term adjustments.
Regulatory and Market Context
- The patent pertains to compounds comparable to existing NSAIDs but with potentially distinct activity profiles.
- Marketed drugs with similar mechanisms include celecoxib and rofecoxib, with patent expirations completed.
- The patent’s scope targets specialty drug development rather than broad NSAID market dominance.
Summary of Critical Points
- The patent claims cover specific heterocyclic compounds with anti-inflammatory potential.
- Claims are broad in derivative and formulation scope but limited structurally.
- Global patent family indicates strategic positioning; expiration in 2020 creates opportunities for generics.
- The patent landscape includes prior art in heterocyclic anti-inflammatory agents, with no known litigations associated directly.
Key Takeaways
- US Patent 6,485,748’s claims protect specific heterocyclic compounds for inflammation.
- Its expiration permits market entry for generic rivals, assuming no other patents restrict the pathway.
- The patent landscape shows ongoing innovation in heterocyclic NSAIDs and inflammatory agents.
- Effective enforcement or licensing agreements could impact market dynamics, especially around drugs targeting similar pathways.
- The patent’s narrow structural claims limit scope but are integral in progressing specific anti-inflammatory therapeutics.
FAQs
1. Does US Patent 6,485,748 cover all heterocyclic anti-inflammatory agents?
No. It claims specific compounds within a defined structural class, not all heterocyclic NSAIDs.
2. Are the claims valid after the patent’s expiration in 2020?
Yes. Patent rights cease unless extensions are granted or other patents cover similar compounds.
3. Can a competing company develop similar compounds after 2020?
Yes, provided they do not infringe on other active patents or formulations.
4. How does this patent relate to other anti-inflammatory patents?
It exists within a crowded landscape with prior art patents focusing on heterocyclic compounds. Its specific claims add to this portfolio but are not comprehensive of all NSAID compounds.
5. Is there ongoing litigation related to US Patent 6,485,748?
No public records show active lawsuits or disputes involving this patent.
References
[1] U.S. Patent Office. Patent number 6,485,748.
[2] Patent landscape reports for heterocyclic anti-inflammatory agents, 2000-2005.
[3] European Patent Office filings related to heterocyclic NSAIDs.
More… ↓
⤷ Start Trial
|
